Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice

European Journal of Heart Failure

Volumn 11, Issue 7, 2009, Pages 638-647

  Nielsen, Jan M ^a   Kristiansen, Steen B ^a   Nørregaard, Rikke ^a   Andersen, Claus L ^a   Denner, Larry ^b   Nielsen, Torsten T ^a   Flyvbjerg, Allan ^c   Bøtker, Hans E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Clinical Institute   (Denmark)

Author keywords

Advanced Glycation end products; Conductance catheter; db db mice; Diabetic cardiomyopathy; Heart failure; RAGE

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; MYOSIN; RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GLYCATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RNA EXTRACTION; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIOMYOPATHIES; COMPLICATION; DISEASE MODEL; GENETICS; HEART FUNCTION TEST; HEART MUSCLE; HUMAN; MALE; METABOLISM; PATHOLOGY; RISK FACTOR; SYSTOLE;

ANALYSIS OF VARIANCE; ANIMALS; CARDIOMYOPATHIES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART FUNCTION TESTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; NITRIC OXIDE SYNTHASE; RISK FACTORS; SYSTOLE;

EID: 67650096803     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp070     Document Type: Article

References (39)

1. Yan SF, Barile GR, D'Agati V, Du YS, Ramasamy R, Schmidt AM. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007; 7:146-153.
2. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280:E685-E694.
3. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35:365-380.
4. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008; 295:H491-H498.
5. Cooper ME. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 2004; 17:31S-38S.
6. Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 2002; 34:1425-1431.
7. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 2005; 97:305-311.
8. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92:785-792.
9. Casselmann C, Reimann A, Friedrich I, Schubert A, Silber RE, Simm A. Age- dependent expression of advanced glycation end product receptor genes in the human heart. Gerontology 2004; 50:127-134.
10. Simm A, Casselmann C, Schubert A, Hofmann S, Reimann A, Silber RE. Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction. Exp Gerontol 2004; 39:407-413.
11. Sun M, Yokoyama M, Ishiwata T, Asano G. Deposition ofadvanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int JExp Pathol 1998; 79:207-222.
12. Ahmed N, ThornalleyPJ. Advanced glycation endproducts: whatistheir relevance to diabetic complications? Diabetes Obes Metab 2007; 9:233-245.
13. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007; 27:130-143.
14. Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG,Malhotra A. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003; 285:H2587-H2591.
15. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93:1905-1912.
16. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R. Long-Term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53:166-172.
17. Nielsen JM, Kristiansen SB, Ringgaard S, Nielsen TT, Flyvbjerg A, Redington AN, Botker HE. Left ventricular volume measurement in mice by conductance catheter: evaluation and optimization of calibration. Am J Physiol Heart Circ Physiol 2007; 293:H534-H540.
18. Grossman W, McLaurin LP, Stefadouros MA. Left ventricular stiffness associated with chronic pressure and volume overloads in man. Circ Res 1974; 35:793 -800.
19. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemicsensitivityin hearts from db/db mice. Diabetes 2003; 52:434-441.
20. Van den Bergh A, FlamengW, Herijgers P. Type II diabetic mice exhibitcontractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 2006; 8:777-783.
21. Picano E. Diabetic cardiomyopathy: the importance of being earliest. J Am Coll Cardiol 2003; 42:454-457.
22. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001; 24:5-10.
23. Andersen NH, Poulsen SH, Eiskjaer H, Poulsen PL, Mogensen CE. Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with Type II diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clin Sci (Lond) 2003; 105:59-66.
24. Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection ofearlydiabetic myocardial disease. JAm Coll Cardiol 2003; 41:611 -617.
25. Bierhaus A, HumpertPM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM,Nawroth PP. Understanding RAGE, the receptor for advanced glycation end products. JMol Med 2005; 83:876-886.
26. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955.
27. Mason DT, Braunwald E, Covell JW, Sonnenblick EH, Ross J Jr. Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation 1971; 44:47-58.
28. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van d V, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117:43 -51.
29. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, Davies PJ, Taegtmeyer H. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. JMol Cell Cardiol 2000; 32:985-996.
30. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ,Cooksey RC, Litwin SE, Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146:5341 -5349.
31. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S,Davies PJ, Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 1998; 4:1269-1275.
32. Yue P, Arai T, Terashima M, Sheikh AY, Cao F, Charo DN, Hoyt G, Robbins RC, Ashley EA, Wu JC, Yang PC, Tsao PS. Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. Am JPhysiol Heart Circ Physiol 2007; 292:H2106-H2118.
33. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyo- pathy. Mol Cell Biochem 1998; 180:53-57.
34. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, SaffitzJE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001; 107:813 -822.
35. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002; 105:1861 -1870.
36. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26:650-661.
37. Diaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P, Chrolavicius S, Zhu J, Kazmi K, Liu L, Budaj A, Zubaid M, Avezum A, Ruda M, Yusuf S. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocar- dial infarction. JAMA 2007; 298:2399-2405.
38. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992; 359:843 -845.
39. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O,Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen- activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50:1495-1504.